Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: Edscharp who wrote (443)	5/11/1999 10:32:00 PM
From: Edscharp	Respond to of 712

Anybody who believes in the validity of technical charting may find this interesting: equities.barchart.com

To: Edscharp who wrote (443)	5/12/1999 11:28:00 AM
From: Biomaven	Read Replies (2) \| Respond to of 712

Centocor's market cap, at $3.2 billion, is over ten times that of Cor This may have a little something to do with the fact that, despite its narrower indication, ReoPro sales are over 10 times as high as Integrilin sales. Bleeding has not been a substantial issue with ReoPro, and if need be its effects are pretty much instantly reversed by infusing platelets (because it binds so tightly, the drug doesn't hang around long). CORR may well be undervalued, but not because it is suddenly going to steal the market from CNTO. Peter